Vasculitides represent such a heterogeneous group of disorders that difficulties arise in their classification. Although biopsy examination of involved tissues remains essential, new serological markers have been developed. Therapeutic strategies have been refined, and B lymphocyte-targeted drugs may prove a satisfactory alternative.